Literature DB >> 9312310

The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers.

I D Cockshott1, S D Oliver, J J Young, K J Cooper.   

Abstract

'Casodex' (bicalutamide) is an orally active, non-steroidal, pure antiandrogen; it is a racemate with antiandrogenic activity residing predominantly in the (R)-enantiomer. Healthy male volunteers (n = 15) were administered single oral doses of bicalutamide (50 mg) after food and after fasting as part of a three-treatment, three-period, randomized cross-over study, with a 9 week washout. After fasting, plasma concentrations of (R)-bicalutamide were much higher than those of (S)-bicalutamide; the mean (R)-enantiomer Cmax (734 ng mL-1) was about nine times higher than the (S)-enantiomer value (84 ng mL-1). The corresponding tmax values were 19 and 3 h for (R)- and (S)-bicalutamide, respectively. Elimination of (R)-bicalutamide from plasma was monoexponential and slow (t1/2 = 5.8 d). Elimination of (S)-bicalutamide was biphasic in some volunteers but monophasic in others (terminal t1/2 =1.2 d; n = 11). There was no significant effect of food on AUC, tmax, or t1/2 data for either enantiomer. The observed slightly higher values of Cmax for (R)-bicalutamide (14%) and (S)-bicalutamide (19%), when dosing with food, achieved statistical significance. However, differences of this magnitude are unlikely to to be of any clinical relevance. These data indicate that 'Casodex' can be taken without reference to meal times; this may be of particular relevance for its indication in a disease of the elderly.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9312310     DOI: 10.1002/(sici)1099-081x(199708)18:6<499::aid-bdd37>3.0.co;2-j

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  8 in total

1.  Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS.

Authors:  Georgia Charkoftaki; Aristides Dokoumetzidis; Georgia Valsami; Panos Macheras
Journal:  Pharm Res       Date:  2012-07-04       Impact factor: 4.200

Review 2.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Predicting effect of food on extent of drug absorption based on physicochemical properties.

Authors:  Chong-Hui Gu; Hua Li; Jaquan Levons; Kimberley Lentz; Rajesh B Gandhi; Krishnaswamy Raghavan; Ronald L Smith
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

Review 4.  Bicalutamide in advanced prostate cancer. A review.

Authors:  K L Goa; C M Spencer
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

Review 5.  Bicalutamide: in early-stage prostate cancer.

Authors:  Christopher I Carswell; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Bicalutamide: clinical pharmacokinetics and metabolism.

Authors:  Ian D Cockshott
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 7.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

8.  Spectrophotometric estimation of bicalutamide in tablets.

Authors:  P P Sancheti; V M Vyas; Manali Shah; Poonam Karekar; Y V Pore
Journal:  Indian J Pharm Sci       Date:  2008-11       Impact factor: 0.975

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.